Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Piezoelectric device and fabricating method thereof
Circuit for and method of enabling communication of cryptographic data
Methods and systems for determining the reliability of transaction
Hybrid coatings and associated methods of application
Method for implementing dynamic pseudorandom keyboard remapping
Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
Actuators and moveable elements with position sensing
  Randomly Featured Patents
Device for washing and hybridization of biochips
Conveyor mechanism
Chemical analyzer, method for dispensing and dilution cup
Sprayable material for repairing base plates of ingot molds
Boosting to determine indicative features from a training set
Low height VLF antenna system
Method and apparatus for determining coupled path loss
Amonafide salts
Mooring/vessel snap hook device
Three-dimensional hierarchical coupling extraction